Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
36.00    0.00 (0.00%)
Bid:
35.00
Ask:
37.00
Spread: 2.00 (5.714%)
Market Cap: £16.76m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Investor Presentation

11 Mar 2021 07:00

RNS Number : 8680R
Cambridge Cognition Holdings PLC
11 March 2021
 

Cambridge Cognition Holdings plc

("Cambridge Cognition" or the "Company")

 

Investor Presentation

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that CEO Matthew Stork and CFO Michael Holton will provide a live investor presentation on Tuesday 23 March at 6.00 p.m. London time. This follows the anticipated release of the Company's preliminary results for the year ended 31 December 2020 at 7:00 a.m. on 23 March 2021.

 

The presentation is open to all existing and potential shareholders. Those wishing to attend should email cog@investor-focus.co.uk and they will be provided with log in details. There will be the opportunity for participants to ask questions at the end of the presentation. Questions can also be emailed to the above address ahead of the presentation.

 

Enquiries:

 

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Michael Holton, Chief Financial Officer

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

cog@investor-focus.co.uk

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJMMPTMTTBBPB
Date   Source Headline
29th Sep 20167:00 amRNSContract Win
22nd Sep 20167:00 amRNSHalf Yearly Report
20th Sep 20167:00 amRNSContract signed
25th Aug 20167:00 amRNSNotice of Results
18th Aug 201610:27 amRNSHolding(s) in Company
16th Aug 20167:00 amRNSCognition Kit Feasibility Study
20th Jul 20167:00 amRNSContract Win
24th Jun 201612:33 pmRNSResult of AGM
22nd Jun 20167:00 amRNSDistribution Agreement with MANUS Neurodynamica
2nd Jun 20167:00 amRNSDistribution Agreement with AnthroTronix
25th May 20162:00 pmRNSNotice of AGM & Posting of Annual Report
6th May 20167:00 amRNSDirector Dealing
5th May 20167:00 amRNSCANTAB Mobile - submission for FDA clearance
3rd May 20163:06 pmRNSHolding(s) in Company
25th Apr 20162:00 pmRNSDirector Dealing
25th Apr 20167:01 amRNSPlacing to raise £1.25m
25th Apr 20167:00 amRNSFinal Results
11th Apr 20167:00 amRNSCANTAB Recruit release
4th Apr 20167:00 amRNSPresentation of Prototype Wearable
30th Mar 20164:06 pmRNSAppointment of Adviser
16th Mar 20167:00 amRNSTrading Update
1st Mar 20167:00 amRNSWearables partnership
15th Feb 20167:00 amRNSDirectorate Change
8th Dec 20157:00 amRNSNew medical device
20th Nov 20157:00 amRNSYear End Trading Update
8th Oct 20157:00 amRNSTwo software licence agreements
21st Sep 20157:00 amRNSFormation of Cantab Corporate Health Limited
10th Sep 20157:00 amRNSHalf Yearly Report
9th Sep 20157:00 amRNSNew patent application
20th Aug 20157:00 amRNSNotice of Results
22nd Jul 20152:30 pmRNSNew research delivered at AAIC
9th Jul 201512:08 pmRNSDirector dealing and Grant of Options
8th Jul 20155:15 pmRNSRe: Directorate Change
1st Jul 201512:00 pmRNSAppointment of Chief Operating Officer
8th Jun 20158:53 amRNSDirector dealing
2nd Jun 201510:30 amRNSAppointment of Non-Executive Director
27th May 201510:33 amRNSResult of AGM
27th May 20157:00 amRNSAGM Statement
21st May 20153:17 pmRNSIssue of Equity
20th May 20157:00 amRNSNew cognitive assessment product
12th May 20157:01 amRNSInvestor teach-in
6th May 20159:35 amRNSHolding(s) in Company
6th May 20157:02 amRNSNew Applications in Healthcare
1st May 201512:02 pmRNSPosting of Annual Report & Notice of AGM
14th Apr 20157:00 amRNSSales of Cantab Connect iPad product exceed £1m
12th Mar 20157:00 amRNSFinal Results
4th Mar 20157:00 amRNSUS office opened
3rd Mar 20157:00 amRNSNotice of Results
21st Jan 20157:00 amRNSLaunch of new iPad research product
16th Dec 20143:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.